Published in Medical Patent Law Weekly, September 16th, 2009
ACD will use the funds to accelerate the development of its proprietary diagnostic tests based on the company's patent pending RNAscope™ technology. "This second closing marks the achievement of our RNAscope™ technology development milestones, including in situ detection of single RNA molecules in blood and FFPE tissues, multiplex analysis, and full assay automation," said Dr. Yuling Luo, Founder, President and CEO of ACD. "We can now offer our...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Patent Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.